

# Sam Schulman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6469297/publications.pdf>

Version: 2024-02-01

344  
papers

40,661  
citations

12303

69  
h-index

2500

196  
g-index

353  
all docs

353  
docs citations

353  
times ranked

26052  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 692-694.	1.9	3,778
2	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	13.9	2,807
3	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
4	Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 361, 2342-2352.	13.9	2,330
5	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 202-204.	1.9	1,826
6	Prevention of VTE in Nonsurgical Patients. <i>Chest</i> , 2012, 141, e195S-e226S.	0.4	1,780
7	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.4	1,723
8	Evidence-Based Management of Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e152S-e184S.	0.4	1,105
9	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	13.9	951
10	A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1995, 332, 1661-1665.	13.9	928
11	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
12	Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 709-718.	13.9	868
13	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2012, 141, e495S-e530S.	0.4	860
14	Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. <i>Circulation</i> , 2014, 129, 764-772.	1.6	824
15	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , 2014, 124, 1968-1975.	0.6	662
16	Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. <i>Chest</i> , 2008, 133, 257S-298S.	0.4	655
17	Increased fetal loss in women with heritable thrombophilia. <i>Lancet, The</i> , 1996, 348, 913-916.	6.3	640
18	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636

#	ARTICLE	IF	CITATIONS
19	The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1997, 336, 393-398.	13.9	592
20	Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy. <i>American Journal of Medicine</i> , 1998, 104, 332-338.	0.6	481
21	Hemorrhagic Complications of Anticoagulant Treatment. <i>Chest</i> , 2004, 126, 287S-310S.	0.4	452
22	Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. <i>New England Journal of Medicine</i> , 2003, 349, 1713-1721.	13.9	444
23	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet</i> , The, 2014, 383, 880-888.	6.3	425
24	Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 734-742.	1.9	416
25	Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. <i>Chest</i> , 2012, 141, e601S-e636S.	0.4	401
26	2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2022, 53, 101161STR0000000000000407.	1.0	363
27	Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2000, 342, 1953-1958.	13.9	326
28	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. <i>BMJ: British Medical Journal</i> , 2011, 342, d3036-d3036.	2.4	315
29	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
30	Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. <i>Lancet</i> , The, 2006, 368, 371-378.	6.3	278
31	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. <i>British Journal of Haematology</i> , 1999, 105, 1109-1113.	1.2	258
32	Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. <i>Blood</i> , 2017, 130, 1706-1712.	0.6	258
33	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
34	How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. <i>Blood</i> , 2012, 119, 3016-3023.	0.6	226
35	Care of Patients Receiving Long-Term Anticoagulant Therapy. <i>New England Journal of Medicine</i> , 2003, 349, 675-683.	13.9	216
36	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. <i>Chest</i> , 2012, 141, 53S-70S.	0.4	213

#	ARTICLE	IF	CITATIONS
37	The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. <i>Thrombosis and Haemostasis</i> , 1999, 81, 684-689.	1.8	209
38	Diagnosis of Pulmonary Embolism with $\text{D-Dimer}$ Adjusted to Clinical Probability. <i>New England Journal of Medicine</i> , 2019, 381, 2125-2134.	13.9	207
39	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
40	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	0.6	204
41	The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2007, 147, 766.	2.0	192
42	Anticoagulants and Their Reversal. <i>Transfusion Medicine Reviews</i> , 2007, 21, 37-48.	0.9	191
43	Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage. <i>Stroke</i> , 2010, 41, 2860-2866.	1.0	186
44	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	2.6	180
45	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177
46	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. <i>European Respiratory Journal</i> , 2016, 48, 1369-1376.	3.1	159
47	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 842-851.	1.8	157
48	Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 150-157.	1.8	144
49	Cervical artery dissection: Pathology, epidemiology and management. <i>Thrombosis Research</i> , 2009, 123, 810-821.	0.8	143
50	Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.	1.6	133
51	Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. <i>Annals of Internal Medicine</i> , 2009, 150, 293.	2.0	132
52	$\text{D-Dimer}$ Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. <i>Annals of Internal Medicine</i> , 2015, 162, 27-34.	2.0	128
53	Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. <i>Thrombosis Research</i> , 2012, 129, 146-151.	0.8	121
54	Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection. <i>Psychosomatic Medicine</i> , 1995, 57, 32-36.	1.3	100

#	ARTICLE	IF	CITATIONS
55	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
56	Postoperative Low-Molecular-Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	0.5	92
57	Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , 2019, 3, 158-167.	2.5	92
58	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1295-1299.	1.9	91
59	Venous thromboembolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1219-1229.	1.8	88
60	Validation of a composite score for clinical severity of hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1113-1121.	1.9	84
61	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	0.7	84
62	Hypofibrinolytic State in HIV-Infected Patients Treated With Protease Inhibitor-Containing Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 441-449.	0.9	79
63	Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios. <i>Annals of Internal Medicine</i> , 2011, 155, 653.	2.0	79
64	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017, 89, 687-696.	1.5	79
65	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1010-1018.	1.9	77
66	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , 2011, 118, 205-205.	0.6	77
67	Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 652-660.	0.9	76
68	Selective D-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2013, 158, 93.	2.0	73
69	Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER <sup>A</sup> , RE-COVER <sup>B</sup> , and RE-MEDY <sup>C</sup> . <i>Vascular Medicine</i> , 2016, 21, 506-514.	0.8	71
70	Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients. <i>Anesthesiology</i> , 2014, 121, 969-977.	1.3	71
71	Long-term Sequelae of Calf Vein Thrombosis Treated with Heparin or Low-dose Streptokinase. <i>Acta Medica Scandinavica</i> , 1986, 219, 349-357.	0.0	70
72	Advantages and limitations of the new anticoagulants. <i>Journal of Internal Medicine</i> , 2014, 275, 1-11.	2.7	69

#	ARTICLE	IF	CITATIONS
73	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. <i>Chest</i> , 2017, 152, 81-91.	0.4	68
74	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1603-1607.	1.7	66
75	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 684-688.	1.0	66
76	Treatment of bleeding complications in patients on anticoagulant therapy. <i>Blood</i> , 2019, 133, 425-435.	0.6	65
77	Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes. <i>Obstetrics and Gynecology</i> , 2014, 124, 600-609.	1.2	64
78	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	1.8	62
79	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62
80	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	1.9	60
81	Stability of factor VIII concentrates after reconstitution. <i>American Journal of Hematology</i> , 1994, 45, 217-223.	2.0	58
82	New oral anticoagulant agents – general features and outcomes in subsets of patients. <i>Thrombosis and Haemostasis</i> , 2014, 111, 575-582.	1.8	58
83	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	1.3	57
84	Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. <i>Thrombosis and Haemostasis</i> , 2012, 108, 493-498.	1.8	55
85	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	2.2	55
86	Venous Thromboembolism in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1642-1653.	1.8	54
87	Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins. <i>Thrombosis and Haemostasis</i> , 2003, 90, 679-687.	1.8	53
88	Activated prothrombin complex concentrate for dabigatran-associated bleeding. <i>British Journal of Haematology</i> , 2014, 164, 308-310.	1.2	51
89	A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh. <i>Thrombosis and Haemostasis</i> , 1984, 51, 261-265.	1.8	51
90	Graduated compression stockings to treat acute leg pain associated with proximal DVT. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1137-1141.	1.8	48

#	ARTICLE	IF	CITATIONS
91	Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 772-776.	1.5	47
92	Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis. <i>Thrombosis and Haemostasis</i> , 1995, 74, 486-492.	1.8	47
93	Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. <i>Thrombosis Research</i> , 2017, 152, 44-48.	0.8	46
94	Role of Fibrin Sealants in Surgical Procedures on Patients With Hemostatic Disorders. <i>Clinical Orthopaedics and Related Research</i> , 1996, 328, 65-75.	0.7	45
95	Safety and Efficacy of Continuous Infusion of a Combined Factor VIII & von Willebrand Factor (vWF) Concentrate (Haemate-P&#228;,c) in Patients with von Willebrand Disease. <i>Thrombosis and Haemostasis</i> , 1999, 81, 229-233.	1.8	43
96	Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. <i>Thrombosis and Haemostasis</i> , 2014, 111, 233-239.	1.8	43
97	Venous Thromboembolism in Older Adults: A Community-based Study. <i>American Journal of Medicine</i> , 2014, 127, 530-537.e3.	0.6	41
98	DDAVP&#228;"The Multipotent Drug in Patients With Coagulopathies. <i>Transfusion Medicine Reviews</i> , 1991, 5, 132-144.	0.9	39
99	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 099-105.	1.5	39
100	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. <i>Blood</i> , 2017, 129, 3285-3293.	0.6	39
101	Inhibition of Warfarin Activity by Ribavirin. <i>Annals of Pharmacotherapy</i> , 2002, 36, 72-74.	0.9	38
102	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , 2020, 4, 3520-3527.	2.5	38
103	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. <i>BMJ</i> , The, 2021, 373, n1205.	3.0	38
104	Molecular genetic analysis of severe protein&#220;C deficiency. <i>Human Genetics</i> , 2000, 106, 646-653.	1.8	37
105	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. <i>Thrombosis and Haemostasis</i> , 2008, 99, 616-622.	1.8	37
106	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	0.8	37
107	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
108	Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa&#228;"based methods overestimate antithrombin activity in some patients?. <i>Blood</i> , 2002, 99, 2271-2272.	0.6	36

#	ARTICLE	IF	CITATIONS
109	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2045-2052.	1.8	36
110	Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 0421-0424.	1.5	35
111	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. <i>Thrombosis and Haemostasis</i> , 2010, 104, 118-121.	1.8	34
112	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1144-1152.	1.9	34
113	Direct and indirect costs of management of long-term warfarin therapy in Canada. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2192-2200.	1.9	33
114	Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. <i>Thrombosis and Haemostasis</i> , 2017, 117, 491-499.	1.8	33
115	Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1495-1500.	1.9	33
116	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, 29-35.	2.0	33
117	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 282-290.	1.0	32
118	Heparin, DDAVP and the Bleeding Time. <i>Thrombosis and Haemostasis</i> , 1991, 65, 242-244.	1.8	32
119	Management of venous thromboembolism: an update. <i>Thrombosis Journal</i> , 2016, 14, 23.	0.9	31
120	Hepatitis E virus infection in hemophiliacs. <i>Journal of Medical Virology</i> , 1995, 46, 153-156.	2.5	30
121	Pregnancy, Heparin and Osteoporosis. <i>Thrombosis and Haemostasis</i> , 2002, 87, 180-181.	1.8	30
122	Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1143-1146.	1.8	30
123	Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners. <i>Scandinavian Journal of Infectious Diseases</i> , 1990, 22, 393-397.	1.5	28
124	New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 258-266.	1.8	28
125	Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 657-660.	0.5	28
126	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28



#	ARTICLE	IF	CITATIONS
127	Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1203-1210.	0.8	28
128	Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 347-353.e1.	0.9	28
129	Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. <i>American Heart Journal</i> , 2018, 195, 108-114.	1.2	28
130	Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B. <i>Acta Haematologica</i> , 1995, 94, 35-42.	0.7	27
131	An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. <i>Haemophilia</i> , 2006, 12, 223-227.	1.0	27
132	Accuracy and safety of 99mTc-labeled anti-D-dimer (DI-80B3) Fabâ€™™ fragments (ThromboViewÂ®) in the diagnosis of deep vein thrombosis: A phase II study. <i>Thrombosis Research</i> , 2012, 130, 381-389.	0.8	27
133	Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. <i>Thrombosis Research</i> , 2016, 147, 97-101.	0.8	27
134	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 517-521.	0.9	27
135	The feasibility of using concentrates containing factor IX for continuous infusion. <i>Haemophilia</i> , 1995, 1, 103-110.	1.0	26
136	Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1254-1259.	1.9	26
137	Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. <i>Thrombosis Journal</i> , 2008, 6, 15.	0.9	25
138	Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1984, 52, 276-280.	1.8	25
139	Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1177-1180.	1.8	24
140	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	1.8	24
141	Treatment of acute pulmonary embolism with dabigatran versus warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 714-721.	1.8	24
142	Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 279-290.	2.3	23
143	Good practice statements for antithrombotic therapy in the management of COVIDâ€™19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
144	Transmission of HIV Infection to Heterosexual Partners but Not to Household Contacts of Seropositive Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1986, 18, 497-500.	1.5	22

#	ARTICLE	IF	CITATIONS
145	Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT. <i>Thrombosis and Haemostasis</i> , 1985, 53, 137-140.	1.8	22
146	Psychosocial Self-Prognosis in Relation to Mortality and Morbidity in Hemophiliacs with HIV Infection. <i>Psychotherapy and Psychosomatics</i> , 1994, 62, 185-192.	4.0	21
147	Recombinant FVIIa in children with liver disease. <i>Thrombosis Research</i> , 2005, 116, 185-197.	0.8	21
148	Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 115, 291-298.	1.8	21
149	Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 1997, 78, 693-698.	1.8	21
150	A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. <i>Drug Safety</i> , 2011, 34, 449-463.	1.4	20
151	Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etxilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , 2012, 120, 21-21.	0.6	20
152	The fixed flexed and subluxed knee in the haemophilic child: what should be done?. <i>Haemophilia</i> , 1996, 2, 47-50.	1.0	19
153	Coagulation factor concentrates by continuous infusion. <i>Transfusion Medicine Reviews</i> , 1997, 11, 56-63.	0.9	19
154	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. <i>Thrombosis and Haemostasis</i> , 2013, 110, 184-190.	1.8	19
155	Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 486-495.	1.0	19
156	Pharmacologic tools to reduce bleeding in surgery. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 517-21.	0.9	19
157	Effects of factor VIII concentrates on the immune system in hemophilic patients. <i>Annals of Hematology</i> , 1991, 63, 145-151.	0.8	18
158	Periprocedural Management of Direct Oral Anticoagulants. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 127-129.	1.1	18
159	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	0.8	18
160	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.	1.8	18
161	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017316.	1.6	18
162	Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden. <i>Acta Medica Scandinavica</i> , 1984, 215, 249-256.	0.0	17

#	ARTICLE	IF	CITATIONS
163	Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. <i>Blood</i> , 2011, 117, 2089-2092.	0.6	17
164	The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 07-15.	1.5	17
165	Bile acids and coagulation factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 152-158.	0.8	17
166	When the Rubber Meets the Road: Adherence and Persistence with Non-Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real World? A Problem or A Myth?. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 852-859.	1.5	17
167	Management of recurrent venous thromboembolism in patients with cancer: A review. <i>Thrombosis Research</i> , 2018, 164, S172-S177.	0.8	17
168	Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. <i>Thrombosis Research</i> , 2016, 145, 143-148.	0.8	16
169	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. <i>European Respiratory Review</i> , 2018, 27, 180094.	3.0	16
170	Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. <i>Thrombosis and Haemostasis</i> , 2005, 94, 522-527.	1.8	16
171	Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. <i>PLoS ONE</i> , 2018, 13, e0191137.	1.1	16
172	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 641-650.	1.9	15
173	Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage. <i>Stroke</i> , 2011, 42, 3663-3664.	1.0	15
174	Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. <i>Expert Review of Hematology</i> , 2018, 11, 37-44.	1.0	15
175	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , 2020, 4, 1539-1553.	2.5	15
176	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	1.5	15
177	Pulmonary Hypertension in Hemophilia. <i>Annals of Internal Medicine</i> , 1988, 109, 759.	2.0	14
178	Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C34-C40.	0.8	14
179	Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. <i>British Journal of Haematology</i> , 2006, 133, 68-77.	1.2	14
180	Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. <i>Current Medical Research and Opinion</i> , 2006, 22, 1813-1823.	0.9	14

#	ARTICLE	IF	CITATIONS
181	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008, 263, 412-419.	2.7	14
182	Treatment of venous thromboembolism with dabigatran. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 410-415.	1.2	14
183	Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 513-519.	1.1	14
184	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	0.8	14
185	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	1.8	14
186	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. <i>Anesthesiology</i> , 2019, 131, 1153-1165.	1.3	14
187	New-Onset Atrial Fibrillation in Sepsis: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 018-025.	1.5	14
188	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. <i>Blood Transfusion</i> , 2013, 11, 533-40.	0.3	14
189	Molecular genetic analysis of severe protein C deficiency. <i>Human Genetics</i> , 2000, 106, 646-653.	1.8	13
190	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. <i>Seminars in Hematology</i> , 2011, 48, 46-54.	1.8	13
191	Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: A randomized trial. <i>Thrombosis Research</i> , 2014, 134, 814-818.	0.8	13
192	Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 427-433.	1.0	13
193	Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 582-582.	0.6	13
194	HIV serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. <i>European Journal of Haematology</i> , 1988, 41, 459-466.	1.1	12
195	Management of bleeding complications in patients with cancer on DOACs. <i>Thrombosis Research</i> , 2016, 140, S142-S147.	0.8	12
196	Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 150-156.	1.5	12
197	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	1.9	12
198	Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RECOVER study patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2495-2503.	1.9	12

#	ARTICLE	IF	CITATIONS
199	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2618-2628.	1.9	12
200	Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. <i>Thrombosis Research</i> , 2010, 125, 393-397.	0.8	11
201	Advances in the management of venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 361-377.	0.7	11
202	Thrombin generation test in children and adolescents with chronic liver disease. <i>Thrombosis Research</i> , 2015, 135, 382-387.	0.8	11
203	Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 709-723.	1.5	11
204	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	1.1	11
205	HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. <i>Aids</i> , 1988, 2, 107-112.	1.0	10
206	Limited Protective Effect of the CCR5 $\Delta$ 32/CCR5 $\Delta$ 32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus. <i>Journal of Infectious Diseases</i> , 2003, 187, 215-225.	1.9	10
207	Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran. <i>Haemophilia</i> , 2004, 10, 751-755.	1.0	10
208	Current strategies in prophylaxis and treatment of venous thromboembolism. <i>Annals of Medicine</i> , 2008, 40, 352-359.	1.5	10
209	Extended Anticoagulation in Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 2328-2329.	13.9	10
210	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	1.0	10
211	Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 430-436.	1.0	10
212	Bleeding Complications and Management on anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 886-892.	1.5	10
213	Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 557-561.	1.0	10
214	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. <i>Thrombosis Research</i> , 2019, 182, 12-19.	0.8	10
215	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1661-1671.	1.9	10
216	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 500-513.	2.5	10

#	ARTICLE	IF	CITATIONS
217	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PEâ„ Study. <i>American Journal of Medicine</i> , 2020, 133, 936-945.	0.6	10
218	Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 212-212.	0.6	10
219	Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 2375-2375.	0.6	10
220	Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1255-1264.	1.8	10
221	Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. <i>Thrombosis and Haemostasis</i> , 2005, 94, 820-4.	1.8	10
222	Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. <i>BMJ</i> , The, 0, , e067378.	3.0	10
223	Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis. <i>Human Genetics</i> , 1992, 89, 685-6.	1.8	9
224	Haemorrhagic and Thromboembolic Complications versus Intensity of Treatment of Venous Thromboembolism with Oral Anticoagulants. <i>Acta Medica Scandinavica</i> , 2009, 224, 425-430.	0.0	9
225	A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. <i>Thrombosis and Haemostasis</i> , 2011, 105, 232-238.	1.8	9
226	Anticoagulation Control with Daily Lowâ„Dose Vitamin K to Reduce Clinically Adverse Outcomes and International Normalized Ratio Variability: A Systematic Review and Metaâ„Analysis. <i>Pharmacotherapy</i> , 2013, 33, 1184-1190.	1.2	9
227	Pregnancy, heparin and osteoporosis. <i>Thrombosis and Haemostasis</i> , 2002, 87, 180-1.	1.8	9
228	Local venous infusion of streptokinase in DVT. <i>Thrombosis Research</i> , 1984, 34, 213-216.	0.8	8
229	HIV Infection in a Defined Population of Swedish Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1987, 19, 159-166.	1.5	8
230	Major surgery seems not to influence HIV disease progression in haemophilia patients. <i>British Journal of Haematology</i> , 1998, 103, 10-14.	1.2	8
231	The Role of Ximelagatran in the Treatment of Venous Thromboembolism. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 18-24.	0.5	8
232	STUDIES ON THE MEDICAL TREATMENT OF DEEP VEIN THROMBOSIS. <i>Acta Medica Scandinavica</i> , 1985, 218, 3-68.	0.0	8
233	Less menorrhagia for women with VTE. <i>Blood</i> , 2016, 127, 1378-1379.	0.6	8
234	Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 180-185.	1.0	8

#	ARTICLE	IF	CITATIONS
235	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot and Feasibility Studies, 2020, 6, 52.	0.5	8
236	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 1112-1115.	1.9	8
237	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. Seminars in Thrombosis and Hemostasis, 2020, 46, 977-985.	1.5	8
238	COVID-19, hemostasis disorders and risk of thrombotic complications. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 306-317.	0.2	8
239	Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery. Thrombosis Research, 2015, 135, 841-845.	0.8	7
240	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. Thrombosis and Haemostasis, 2016, 116, 480-485.	1.8	7
241	Update on the Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2016, 42, 891-898.	1.5	7
242	Development of a standardized definition of pulmonary embolism-related death: A cross-sectional survey of international thrombosis experts. Journal of Thrombosis and Haemostasis, 2020, 18, 1415-1420.	1.9	7
243	Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.. Blood, 2009, 114, 1-1.	0.6	7
244	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. Blood, 2012, 120, 19-19.	0.6	7
245	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12650.	1.0	7
246	Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. Haematologica, 2008, 93, 1273-1275.	1.7	6
247	Getting intimate with the venous thrombus. Journal of Thrombosis and Haemostasis, 2009, 7, 1266-1267.	1.9	6
248	Respiratory Review of 2013: Pulmonary Thromboembolism. Tuberculosis and Respiratory Diseases, 2013, 75, 89.	0.7	6
249	Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVERÂ®, RE-COVERÂ®, II, and RE-MÉDYÂ®,. Journal of Thrombosis and Thrombolysis, 2017, 43, 484-489.	1.0	6
250	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	0.8	6
251	Are NSAIDs Double Trouble?. Journal of the American College of Cardiology, 2018, 72, 268-270.	1.2	6
252	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. Journal of Thrombosis and Haemostasis, 2019, 17, 499-506.	1.9	6

#	ARTICLE	IF	CITATIONS
253	Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 1136-1136.	0.6	6
254	Anticoagulation in venous Thrombosis. <i>Journal of the Royal Society of Medicine</i> , 1996, 89, 624-630.	1.1	5
255	NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 264-272.	1.0	5
256	Optimal reversal of vitamin K antagonists. <i>Thrombosis Research</i> , 2007, 119, 15-16.	0.8	5
257	Dabigatran Etxilate: Future Directions in Anticoagulant Treatment. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 32S-41S.	0.7	5
258	Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. <i>Thrombosis and Haemostasis</i> , 2012, 108, 872-875.	1.8	5
259	Secondary prevention of venous thromboembolism. <i>BMJ</i> , The, 2013, 347, f5440-f5440.	3.0	5
260	Distal deep vein thrombosis – a benign disease?. <i>Thrombosis Research</i> , 2014, 134, 5-6.	0.8	5
261	Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 449-453.	0.1	5
262	Direct Oral Anticoagulants in the Real World. <i>Canadian Journal of Nursing Research</i> , 2017, 49, 105-107.	0.6	5
263	Is venous thromboembolism a preventable cause of death?. <i>Lancet Haematology</i> , the, 2020, 7, e555-e556.	2.2	5
264	Anticoagulant Treatment of COVID-19 as Early as Possible – Sulodexide and Perspectives. <i>Thrombosis and Haemostasis</i> , 2021, 121, 849-853.	1.8	5
265	Thermography in the Diagnosis of DVT. <i>Thrombosis and Haemostasis</i> , 1981, 46, 652-654.	1.8	5
266	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. <i>Blood</i> , 2012, 120, 393-393.	0.6	5
267	Ximelagatran for the secondary prevention of venous thromboembolism. A complementary follow-up analysis of the THRIVE III Study. <i>Thrombosis and Haemostasis</i> , 2005, , .	1.8	5
268	A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 159-167.	1.0	5
269	Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/vWF axis in patients with severe COVID-19. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 228-243.	0.2	5
270	Duration of anticoagulants in acute or recurrent venous thromboembolism. <i>Current Opinion in Pulmonary Medicine</i> , 2000, 6, 321-325.	1.2	4



#	ARTICLE	IF	CITATIONS
271	The plasma concentration of activated protein C appears normal in patients with haemophilia. <i>Haemophilia</i> , 2009, 15, 566-570.	1.0	4
272	Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 705-713.	0.5	4
273	Optimal Duration of Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 141-146.	1.5	4
274	Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons. <i>Thrombosis Research</i> , 2017, 160, 38-40.	0.8	4
275	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. <i>Thrombosis Research</i> , 2018, 171, 62-67.	0.8	4
276	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2527-2527.	0.6	4
277	Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 033-036.	1.5	3
278	Thromboprophylaxis in Medical Patients – Why Not For All?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 141-145.	0.5	3
279	Determinants of Bleeding Risk in Patients on Antithrombotic and Antifibrinolytic Drugs. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 762-771.	1.5	3
280	New aspects on treatment modalities for thromboembolic episodes. <i>Journal of Internal Medicine</i> , 2010, 268, 109-119.	2.7	3
281	Is the warfarin saga over?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012, 42, 51-55.	0.2	3
282	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e005674-e005674.	0.8	3
283	Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 160-165.	1.5	3
284	Recent Advances in Thrombosis and Hemostasis – Part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 805-807.	1.5	3
285	Recent Advances in Thrombosis and Hemostasis – Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 809-810.	1.5	3
286	Splanchnic vein thrombosis: what are the long-term risks?. <i>Lancet Haematology, the</i> , 2018, 5, e431-e432.	2.2	3
287	Recent Advances in Thrombosis and Hemostasis – Part III. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 312-314.	1.5	3
288	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3

#	ARTICLE	IF	CITATIONS
289	Recent Advances in Thrombosis and Hemostasis—Part VII. Seminars in Thrombosis and Hemostasis, 2021, 47, 621-622.	1.5	3
290	MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. BMJ Open, 2021, 11, e049557.	0.8	3
291	Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. The Hematology Journal, 2002, 3, 311-314.	2.0	3
292	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	0.6	3
293	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thrombosis and Haemostasis, 2021, 0, .	1.8	3
294	Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thrombosis and Haemostasis, 2003, 89, 741-6.	1.8	3
295	Long-Term Prophylaxis in Venous Thromboembolism: LMWH or Oral Anticoagulation?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 17-21.	0.5	2
296	A Step Change in Oral Anticoagulation: Lack of Coagulation Monitoring with Ximelagatran. Seminars in Vascular Medicine, 2005, 5, 259-265.	2.1	2
297	Tossing a coin or using common sense. Journal of Thrombosis and Haemostasis, 2013, 11, 432-434.	1.9	2
298	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. Thrombosis Research, 2013, 131, 300-303.	0.8	2
299	Reply to Dr Lessire et al. Regional Anesthesia and Pain Medicine, 2016, 41, 788.	1.1	2
300	Accumulating data on rivaroxaban for venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 2017, 117, 1840-1840.	1.8	2
301	Recent Advances in Thrombosis and Hemostasis—Part IV. Seminars in Thrombosis and Hemostasis, 2019, 45, 130-131.	1.5	2
302	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. TH Open, 2020, 04, e255-e262.	0.7	2
303	The onerous task of comparing treatments in inhibitor patients. Thrombosis and Haemostasis, 2007, 98, 710-712.	1.8	2
304	Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.. Blood, 2004, 104, 710-710.	0.6	2
305	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. Blood, 2009, 114, 1872-1872.	0.6	2
306	Elevated Risk of Venous but Not Arterial Thrombosis in Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma. Blood, 2012, 120, 1603-1603.	0.6	2

#	ARTICLE	IF	CITATIONS
307	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013, 122, 460-460.	0.6	2
308	Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study. <i>Journal of Surgical Oncology</i> , 2022, 126, 386-393.	0.8	2
309	Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 358-359.	3.3	1
310	Rivaroxaban in Orthopedic Surgery – A Change of Paradigm?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 613-620.	0.7	1
311	New anticoagulants in atrial fibrillation management. <i>Thrombosis Research</i> , 2013, 131, S63-S66.	0.8	1
312	American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. <i>Chest</i> , 2013, 143, 1191.	0.4	1
313	Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis.. <i>Blood</i> , 2012, 120, 2258-2258.	0.6	1
314	Recent Advances in Thrombosis and Hemostasis: Part VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 863-864.	1.5	1
315	Recent Advances in Thrombosis and Hemostasis – Part VIII. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 405-406.	1.5	1
316	No Evidence for Vertical Transmission in Children Born to HIV Seropositive Male Haemophiliacs. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 141-143.	1.5	0
317	Coping Style in Relation to the Consumption of Factor Concentrate in HIV-Infected Hemophiliacs during the Years after Their Infection Became Known. <i>Psychotherapy and Psychosomatics</i> , 1994, 61, 205-210.	4.0	0
318	For How Long Should the Treatment with Vitamin K Antagonists Be Maintained?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 89-90.	0.5	0
319	Optimization of Treatment for Venous Thromboembolism and Prevention of Recurrences. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 79-80.	0.5	0
320	Ximelagatran in the Clinic: Practical Management of Patients. <i>Seminars in Vascular Medicine</i> , 2005, 5, 301-307.	2.1	0
321	Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 472-473.	3.3	0
322	Antithrombotic Therapy. , 2012, , 171-177.		0
323	The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 566-567.	1.9	0
324	Prolonged Bleeding After Surgery. , 2014, , 151-160.		0

#	ARTICLE	IF	CITATIONS
325	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". <i>Circulation</i> , 2014, 130, e95.	1.6	0
326	Matching genes with constitution and environment. <i>Thrombosis and Haemostasis</i> , 2016, 116, 592-594.	1.8	0
327	Acute Unilateral Renal Infarction in the Setting of an Inherited Thrombophilia and Atrial Septal Defect. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	0
328	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1398-1399.	1.9	0
329	Recent Advances in Thrombosis and Hemostasis"Part V. Seminars in Thrombosis and Hemostasis, 2019, 45, 757-759.	1.5	0
330	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 561-570.	1.0	0
331	Anticoagulants for the Treatment of Venous Thromboembolism. <i>Fundamental and Clinical Cardiology</i> , 2009, , 155-170.	0.0	0
332	Perioperative Management Of Patients On Dabigatran " a Prospective Cohort Study. <i>Blood</i> , 2013, 122, 3637-3637.	0.6	0
333	Incidence and Risk Factors for Venous Thromboembolism in Patients with Spinal Cord Injury: A Retrospective Study. <i>Blood</i> , 2016, 128, 1440-1440.	0.6	0
334	Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study. <i>Blood</i> , 2018, 132, 5060-5060.	0.6	0
335	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant"Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 333.	2.6	0
336	Pregnancy-related pelvic vein thrombosis. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 627-632.	0.2	0
337	Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 255-256.	0.7	0
338	A Phase 3, Randomized, Double-Blinded Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Direct Oral Anticoagulant Therapy with Factor Xa Inhibitor: The Lex-210 Study. <i>Blood</i> , 2021, 138, 3235-3235.	0.6	0
339	Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability. <i>Blood</i> , 2020, 136, 20-20.	0.6	0
340	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. <i>ACP Journal Club</i> , 2003, 139, 42.	0.1	0
341	Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects. <i>ACP Journal Club</i> , 2005, 143, 8.	0.1	0
342	Extension of anticoagulation after venous thromboembolism - risk factors influencing the decision. <i>Hamostaseologie</i> , 2008, 28, 110-9.	0.9	0

#	ARTICLE	IF	CITATIONS
343	High factor VIII levels and recurrent thromboembolism in patients with and without inflammatory bowel disease: a retrospective comparative study. TH Open, 0, 0, .	0.7	0
344	Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP Journal Club, 2003, 139, 42.	0.1	0